11.09.12
Kalamazoo, Mich.-based Stryker Corp., has completed its acquisition of Surpass Medical Ltd. Surpass is developing and commercializing the NeuroEndGraft family of flow diversion stent technology to treat brain aneurysms using a mesh design and delivery system.
“With the acquisition of Surpass Medical we are continuing to expand our global product portfolio in the fast growing and neurovascular market by offering patients and caregivers differentiated products focused on Complete Stroke Care,” said Kevin A. Lobo, Stryker president and CEO.
When the acquisition was first announced in mid-October, company officials said they expected it to be neutral to Stryker’s 2012 earnings per share excluding purchase and integration-related charges.
Stryker offers reconstructive, medical, and surgical products in the neurotechnology and orthopedics spaces.
“With the acquisition of Surpass Medical we are continuing to expand our global product portfolio in the fast growing and neurovascular market by offering patients and caregivers differentiated products focused on Complete Stroke Care,” said Kevin A. Lobo, Stryker president and CEO.
When the acquisition was first announced in mid-October, company officials said they expected it to be neutral to Stryker’s 2012 earnings per share excluding purchase and integration-related charges.
Stryker offers reconstructive, medical, and surgical products in the neurotechnology and orthopedics spaces.